Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer

Background: Previous prospective studies have shown that eribulin improves the survival in patients with metastatic breast cancer (MBC). However, the optimal timing of its administration to achieve the longest extended survival and the efficacy of using eribulin monotherapy as earlier-line chemother...

Full description

Saved in:
Bibliographic Details
Published in:J Cancer
Main Authors: Shingaki, Sumito, Kogawa, Takahiro, Shimokawa, Mototsugu, Harano, Kenichi, Naito, Yoichi, Kusuhara, Shota, Fujimoto, Yumi, Matsubara, Nobuaki, Hosono, Ako, Mukai, Hirofumi, Onishi, Tatsuya, Hojo, Takashi, Mukohara, Toru
Format: Artigo
Language:Inglês
Published: Ivyspring International Publisher 2020
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7196254/
https://ncbi.nlm.nih.gov/pubmed/32368292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.37670
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items